ReviewFrontiers in medicine2021
Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Assessing the efficacy of infliximab in promoting vascular and mucosal healing in immunoglobulin-resistant kawasaki disease: a meta-analysis.BMC pediatrics · 2025Pooled it
- Different antithrombotic strategies to prevent cardiovascular complications in Kawasaki patients: a systematic review and meta-analysis.BMC pediatrics · 2024Pooled it
- Favorable coronary outcomes following IL-6 blockade with tocilizumab in IVIG-resistant kawasaki disease: a case series.Frontiers in immunology · 2026Article
- From acute immune storm to lifelong vascular risk: a paradigm shift in Kawasaki disease as a chronic disease model.Frontiers in pediatrics · 2026Article
- Kawasaki disease with profound systemic vascular involvements: An insightful pediatric case.Clinical case reports · 2024Article
- Multiresistant Kawasaki Disease in a Young Infant with Giant Aneurysms Growing Fast.Journal of cardiovascular development and disease · 2024Article
- Efficacy of Gamma Globulins in Children with Kawasaki Disease and Factors Influencing Children's Short-Term Prognosis.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD), an acute, generalized vasculitis, is associated with an increased risk of coronary heart disease and is the most common cause of acquired heart disease in childhood. The incidence of KD is increasing worldwide. There are numerous international treatment guidelines. Our study aims to perform the first one so far comparison of them. While the gold standard therapy remains still the same (intravenous immunoglobulins and aspirin), there is currently a lack of evidence for choosing optimal treatment for high-risk patients and refractory KD. In this review, we also discuss the treatment of complications of KD and Kawasaki-like phenotypes, present an anti-inflammatory treatment in the light of new scientific data, and present novel potential therapeutic targets for KD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.